Correlation and diagnostic value of plasma fibrinogen with bone metastasis in prostate cancer patients

doi:10.3877/cma.j.issn.1674-3253.2021.02.011

Abstract

Abstract:

Objective

To explore the correlation and diagnostic value of plasma fibrinogen (Fib) with bone metastasis in prostate cancer patients.

Methods

The clinical data of 148 patients with prostate cancer in the Fifth People's Hospital of Zhangjiagang City from January 2016 to December 2019 were retrospectively analyzed. They were divided into bone metastasis group (n=40) and non-bone metastasis group (n=108). The differences of plasma Fib, prostate specific antigen (PSA), Gleason score and tumor stage were recorded in the two groups. Multi-factor Logistic regression analysis was used to analysis the risk factors of prostate cancer bone metastasis. According to the results of systemic radionuclide bone scan, patients in the bone metastasis group were divided into single bone metastasis group (18 cases) and multiple bone metastasis group (22 cases) according to the number of lesions. The differences in plasma Fib and PSA levels between the two groups were compared. The receiver operating characteristic (ROC) curve was used to analyze the diagnostic value of plasma Fib in prostate cancer bone metastasis.

Results

The plasma Fib and PSA levels in the bone metastasis group were significantly higher than those in the non-bone metastasis group, and the Gleason score >7 and tumor stage T3-4 patients in the bone metastasis group were significantly more than the non-bone metastasis group (P<0.05). The results of multivariate logistic regression analysis showed that increased Fib, Gleason score >7, and tumor stage T3-4 were all independent risk factors for bone metastasis of prostate cancer.The plasma Fib level in the multiple bone metastasis group was significantly higher than that in the single bone metastasis group (P<0.05), but there was no statistically significant difference in plasma PSA levels between the two groups (P>0.05). The area under the ROC curve (AUC) of plasma Fib used to diagnose bone metastases in prostate cancer was 0.742 (95% CI:0.645 to 0.841). When the diagnostic critical value of plasma Fib is 3.61 g/L, its diagnostic efficiency is the highest, with a sensitivity of 68.6% and a specificity of 76.2%.

Conclusion

he plasma Fib level is positively correlated with the degree of prostate cancer bone metastasis, and has certain diagnostic value for the diagnosis of prostate cancer bone metastasis.

Key words: Plasma fibrinogen, Prostate cancer, Bone metastasis, Diagnostic value, Correlation

Hui Zhu, Wudong Tao, Bin Huang, Dongrong Yang, Juan Zhu. Correlation and diagnostic value of plasma fibrinogen with bone metastasis in prostate cancer patients[J]. Chinese Journal of Endourology(Electronic Edition), 2021, 15(02): 135-138.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2021.02.011

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2021/V15/I02/135

Figures/Tables 4

References 19

[1]	Xu Z, Ma T, Zhou J, et al. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis[J].Theranostics, 2020, 10(9): 4201-4216.
[2]	Baptista S, Heleno B, Pinto M,et al.Translation and cultural adaptation of a prostate cancer screening decision aid: a qualitative study in Portugal[J]. BMJ open, 2020, 10(3): e034384.
[3]	李淼沅，袁润强，陈业辉. 前列腺癌并骨转移的治疗新进展[J/CD]. 中华腔镜泌尿外科杂志(电子版). 2018, 12(2): 73-75.
[4]	Wang Y, Singhal U, Qiao Y, et al. Wnt signaling drives prostate cancer bone metastatic tropism and invasion[J]. Transl oncol, 2020, 13(4): 100747.
[5]	John AE.Platelets and fibrinogen: emerging complexity in trauma-induced coagulopathy[J]. Semin Thromb Hemost, 2020, 46(2): 125-133.
[6]	Maconachie S, Jansen M, Cottle E,et al. Viscoelastic haemostatic assays and fibrinogen in paediatric acute traumatic coagulopathy: A comprehensive review[J].Emerg Med Australas, 2020, 32(2): 313-319.
[7]	Dai T, Peng L, Lin G,et al.Preoperative elevated plasma fibrinogen level predicts tumor recurrence and poor prognosis in patients with hepatocellular carcinoma[J].J Gastrointest Oncol, 2019, 10(6): 1049-1063.
[8]	Chen B, Cao DH, Guo JB, et al. Androgen biosynthesis in castration-resistant prostate cancer: Advances in studies][J]. Zhonghua nan ke xue, 2019, 25(3): 265-271.
[9]	中华医学会泌尿外科学分会前列腺癌联盟. 中国前列腺癌早期诊断专家共识[J]. 中华泌尿外科杂志, 2015, 36(8) :561-564.
[10]	Khorasani M, Shahbazi S, Hosseinkhan N. Analysis of differential expression of micrornas and their target genes in prostate cancer: a bioinformatics study on microarray gene expression data[J]. Int J Mol and Cell Med, 2019, 8(2): 103-114.
[11]	Wu FJ, Li IH, Chien WC, et al. Androgen deprivation therapy and the risk of iron-deficiency anaemia among patients with prostate cancer: a population-based cohort study[J]. BMJ open, 2020, 10(3): e034202.
[12]	Askari M, Yazdani A, Yazdani M.Serum levels of total and urine level of PCA3 in patients with benign prostatic hyperplasia and prostate cancer[J]. Ame J clin Exp Urol, 2020, 8(1): 43-47.
[13]	Alwanian WM. Protein tyrosine kinase 6 signaling in prostate cancer[J]. Ame J clin Exp Urol, 2020, 8(1): 1-8.
[14]	Liu W, Li W, Wang Z, et al. Metabolically abnormal obesity increases the risk of advanced prostate cancer in chinese patients undergoing radical prostatectomy[J]. Cancer Manag Res, 2020, 12(1): 1779-1787.
[15]	Tran C, Dicker A, Leiby B, et al. Utilizing digital health to collect electronic patient-reported outcomes in prostate cancer: single-arm pilot trial[J]. J Med Int Res, 2020, 22(3): e12689.
[16]	Sorra E, Aziz MU. Isolated hepatic metastasis of prostate cancer with variable f-fluociclovine uptake by pet/ct imaging[J]. Nucl Med Mol Imaging, 2020, 54(1): 53-57.
[17]	Deek MP. Oligometastatic and oligoprogression disease and local therapies in prostate cancer[J].Cancer J, 2020, 26(2): 137-143.
[18]	Song J, Yu T, Sun Z, et al. Comparison of prognostic significance between serum fibrinogen and global registry of acute coronary events score for prognosis of patients with non-st-elevation acute coronary syndromes undergoing percutaneous coronary intervention[J]. Coron Artery Dis, 2020, 31(2): 124-129.
[19]	Sorra E, Aziz MU. Isolated hepatic metastasis of prostate cancer with variable f-fluociclovine uptake by pet/ct imaging[J]. Nucl Med Mol Imaging, 2020, 54(1): 53-57.

组别	例数	年龄[岁，(±s)]	高血压(例)	糖尿病(例)	吸烟(例)	饮酒(例)	家族史(例)	肌酐[μmol/L，(±s)]
非骨转移组	108	66±8	16	20	25	29	10	70±14
骨转移组	40	70±9	6	4	8	10	5	74±15
统计值		t=1.514	χ²=0.160	χ²=1.559	χ²=0.167	χ²=0.052	χ²=0.075	t=0.928
组别	WBC[×10⁹/L，(±s)]	N[×10⁹/L，(±s)]	Fib[g/L，(±s)]	PSA[ng/ml，(±s)]	Gleason评分(≤7/>7)	肿瘤分期(T1-2/T3-4)
非骨转移组	7.47±1.19	4.49±1.11	2.50±0.49	30±10	78/30	59/49
骨转移组	8.02±1.37	5.08±0.84	3.89±0.59	82±20	22/18	11/29
统计值	t=1.117	t=1.298	t=4.125^*	t=10.268^*	χ²=3.951^*	χ²=8.619^*

组别	例数	年龄[岁，(±s)]	高血压(例)	糖尿病(例)	吸烟(例)	饮酒(例)	家族史(例)	肌酐[μmol/L，(±s)]
非骨转移组	108	66±8	16	20	25	29	10	70±14
骨转移组	40	70±9	6	4	8	10	5	74±15
统计值		t=1.514	χ²=0.160	χ²=1.559	χ²=0.167	χ²=0.052	χ²=0.075	t=0.928
组别	WBC[×10⁹/L，(±s)]	N[×10⁹/L，(±s)]	Fib[g/L，(±s)]	PSA[ng/ml，(±s)]	Gleason评分(≤7/>7)	肿瘤分期(T1-2/T3-4)
非骨转移组	7.47±1.19	4.49±1.11	2.50±0.49	30±10	78/30	59/49
骨转移组	8.02±1.37	5.08±0.84	3.89±0.59	82±20	22/18	11/29
统计值	t=1.117	t=1.298	t=4.125^*	t=10.268^*	χ²=3.951^*	χ²=8.619^*

变量	B	SE	Wald χ²	P值	OR（95% CI）
Fib	1.128	0.336	11.270	<0.001	3.987(2.025～10.998)
PSA	0.625	0.442	1.999	0.128	1.209(0.658～3.220)
Gleason评分>7	0.889	0.267	11.089	<0.001	1.558(1.197～2.698)
肿瘤分期T3-4	1.005	0.355	8.015	0.003	2.112(1.069～4.187)

变量	B	SE	Wald χ²	P值	OR（95% CI）
Fib	1.128	0.336	11.270	<0.001	3.987(2.025～10.998)
PSA	0.625	0.442	1.999	0.128	1.209(0.658～3.220)
Gleason评分>7	0.889	0.267	11.089	<0.001	1.558(1.197～2.698)
肿瘤分期T3-4	1.005	0.355	8.015	0.003	2.112(1.069～4.187)

组别	例数	Fib（g/L）	PSA（ng/mL）
单发骨转移组	18	3.17±0.61	79.22±11.35
多发骨转移组	22	3.92±0.56	85.66±19.38
t值		5.968^*	1.587

Please choose a citation manager

Content to export